Evidence map›Paper›PMID 42625285›Full record

SynthesisAnnals of medicine2026

Prognostic significance of NLRP-3 expression in solid cancers: a systematic review and meta-analysis.

Nishant Thakur, Muhammad Alamgeer, Manu Kumar, Quinton Luong, Jamshid Abdul-Ghafar, Surein Arulananda, Ashley Mansell, Daniel J Gough

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nishant ThakurCentre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Muhammad AlamgeerCentre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Manu KumarDepartment of Animal, Plant and Soil Sciences, La Trobe University, AgriBio, Bundoora, VIC, Australia.
Quinton LuongCentre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Jamshid Abdul-GhafarDepartment of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Surein ArulanandaCentre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Ashley MansellDepartment of Microbiology, Anatomy, Physiology and Pharmacology, La Trobe University, Bundoora, VIC, Australia.
Daniel J GoughCentre for Cancer Research, Hudson Institute of Medical Research, Clayton, VIC, Australia.ORCID 0000-0001-6479-1735

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe inflammasome is a critical immunological sensor comprised of NLRP-3, ASC, and CASPASE-1. Mutations in

methodsPubMed (MEDLINE), Embase, Cochrane, and Google Scholar were searched for articles reporting NLRP-3 expression and disease outcome data in cancer patients. RevMan Review Manager was used to calculate pooled hazard ratios and Mantel-Haenszel pooled odds ratios. RNA sequencing datasets from the TCGA Pan-Cancer (PANCAN) were used for external validation.

resultsPatients with higher NLRP-3 expression showed a significant association with larger tumor size, advanced tumor grade, TNM stage, and presence of metastasis. High NLRP-3 expression has a significant association with poor OS (HR:2.12, 95% CI = 1.49-3.03),

conclusionHigh NLRP-3 expression is associated with advanced disease and poor outcomes in many solid tumours.

Indexed as

NeoplasmsNLR Family, Pyrin Domain-Containing 3 ProteinBiomarkers, TumorGene Expression Regulation, NeoplasticHumansInflammasomesPrognosisBiomarkers, TumorInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanand disease-free survivalcancer stem cellsepithelial–mesenchymal transitionNLRP-3overall survivalprognosistumour microenvironment

Identifiers

PMID42625285
PMCPMC13501775

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.